← Eichor
Condition: Nanoliposomal Irinotecan Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nanoliposomal Irinotecan

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for
Phase 2 · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT07542002NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treat
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07047560Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy
Phase 2 · 3 location(s) · St. Jude Children's Research Hospital · NCT06023641Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07479732Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the
Phase 2 · 1 location(s) · Jiang Long · NCT06531278Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06540326Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
NA · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT07340151Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Phase 2 · 1 location(s) · West China Hospital · NCT06438822Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capec
Phase 2 · 2 location(s) · Affiliated Cancer Hospital of Shantou University Medical Col · NCT07104604Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/Phase 2 · 1 location(s) · National Health Research Institutes, Taiwan · NCT05927857Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT05854498Irinotecan Liposome in Combination With Capecitabine
NA · 1 location(s) · Junjie Hang · NCT06578052Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Phase 2 · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06739928Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07044921Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
NA · 1 location(s) · Kuirong Jiang · NCT06361316Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06184698Liposomal Irinotecan and Apatinib in ES-SCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06749691SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07474103Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Phase 2 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06643793Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectab
Phase 2 · 9 location(s) · Taichung Veterans General Hospital · NCT06816914Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07281157Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405139Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07504471Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
NA · 1 location(s) · Fudan University · NCT06258642New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT07559760Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Phase 2 · 7 location(s) · Tiago Biachi de Castria · NCT06835387Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06210971
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.